
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is positioned for a positive fundamental trajectory because its 3Q results beat expectations, with Adjusted EPS of $0.72 on revenue of $1.345 billion and Adjusted EBITDA of $435 million, while management also narrowed 2026 revenue guidance to $5.200-5.250 billion and expects roughly 64% non-GAAP gross margins and 24% operating margins. The company’s G7 15-Day rollout, lower-cost manufacturing upgrades, and nearly 50% conversion target by year-end support margin expansion, and the newly authorized $1 billion buyback underscores confidence in strong free cash flow generation. Longer term, DexCom’s bull case is reinforced by CONNECT trial data showing a −1.6% A1c reduction versus −0.7% in control, ~97% adherence, and broad reimbursement upside in the large T2NIT market, where CMS coverage could materially expand access.
Bears say
DexCom is facing a deteriorating fundamental profile because its CGM franchise is exposed to rapid product obsolescence, stronger competitor innovation, and the risk that delayed new launches or weaker market adoption could erode revenue and operating results. The company also carries meaningful execution and regulatory risk, including possible Ireland factory ramp issues, post-market safety concerns, recalls, product liability claims, and patent litigation that could interrupt sales, raise costs, or damage its competitive moat. At the same time, global reimbursement pressure from payors and governments, plus inflation-driven higher operating expenses and interest costs, threatens margins and profitability even as the company requires heavy investment to keep pace with a premium-valued diabetes device sector.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About DexCom (DXCM) Forecast
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares